| Released | Contributor | Author | Title | Pages | Price |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Anika Therapeutics | 5 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ANIKA THERAPEUTICS INC (ANIK=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ANIKA THERAPEUTICS INC (ANIK=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ANIKA THERAPEUT -- ANIK | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ANIK , ABIO , GNVC , GTCB , LXRX , NBIX , ORCH -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ANIK: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ANIKA THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
1.48% Nasdaq 
0.04 (0.50%) 
Research Reports
